Physician profile
Rachel E Price
NPI 1679120273
$1,057.56
in general payments reported to CMS, 2019-2025
20 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.48 · 2022: $14.46 · 2023: $107 · 2024: $619 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $215.71 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $139.24 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $117.14 | 2021-2025 | |
| Exact Sciences Corporation | $106.29 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.24 | 2024-2025 | Caplyta |
| Amgen INC. | $52.89 | 2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.79 | 2024 | Jardiance, Ofev |
| Edwards Lifesciences Corporation | $38.19 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Vanda Pharmaceuticals INC. | $35.65 | 2025 | Fanapt |
| Glaxosmithkline, LLC. | $32.27 | 2024 | Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $28.07 | 2025 | Rexulti |
| Lundbeck LLC | $26.82 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $24.26 | 2024 | |
| Paratek Pharmaceuticals, INC. | $19.67 | 2024 | Nuzyra |
| Aimmune Therapeutics, INC. | $19.39 | 2025 | Zenpep |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $18.80 | 2024 | |
| Merck Sharp & Dohme LLC | $17.92 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Pfizer INC. | $17.69 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.43 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $15.10 | 2025 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.